港股異動丨復星醫藥漲近6% 新冠病毒測試劑盒獲藥監局應急審批
格隆匯3月26日丨復星醫藥(2196.HK)漲近6%,報24.45港元,總市值626.6億港元;復星醫藥(600196.SH)午後則放量拉昇逼近漲停。復星醫藥公佈,全資附屬復星長征研製的新型冠狀病毒核酸檢測試劑盒已通過國家藥監局應急審批,獲得醫療器械產品註冊證(註冊證編號:國械注準20203400299)。該產品可於2小時內完成96個樣本的全部檢測;自動化檢測能減少操作人員被感染風險,減少實驗室交叉污染風險,提高檢測效率。另外,3月17日復星長征自主研發的核酸檢測試劑通過了歐盟CE認證,具備歐盟市場的准入條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.